v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:    
Net loss $ (63,264) $ (216,054)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 44,609 46,514
Non-cash interest 4,983 61,557
Amortization of deferred financing costs 275 4,959
Losses from investments in investees 2 9
Equity-based compensation – employees and non-employees 4,973 4,828
Revenue from the receipt of equity (27,269) 0
Realized gain on disposal of fixed assets and sales of equity securities 115 (3,858)
Change in fair value of equity securities and derivative instruments 1,581 1,734
Inducement expense and loss on debt conversion 0 32,647
Deferred income tax (benefit) provision (14,155) (23,137)
Gain on sale of assets (18,070) 0
Changes in assets and liabilities:    
Accounts receivable, net 7,138 19,115
Inventory, net 3,033 (5,915)
Other current assets and prepaid expenses 882 (2,318)
Other assets (298) (510)
Accounts payable 8,865 8,087
Foreign currency measurement 262 (1,989)
Accrued expenses and other liabilities (16,472) (43,643)
Net cash used in operating activities (62,810) (117,974)
Cash flows from investing activities:    
Investments in investees 0 (7,665)
Proceeds from sale of equity securities 0 51,655
Proceeds from the sale of property, plant and equipment 181 181
Capital expenditures (4,837) (6,477)
Proceeds from Labcorp sale 18,392 0
Net cash (used in) provided by investing activities 13,736 37,694
Cash flows from financing activities:    
Share repurchase (17,787) (18,255)
Proceeds from the exercise of common stock options (339) (123)
Borrowings on lines of credit 18,664 16,636
Repayments of lines of credit (18,721) (19,387)
Settlement of convertible notes 0 (62,382)
Net cash used in financing activities (18,183) (83,511)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (1,053) 3,571
Net (decrease) increase in cash, cash equivalents and restricted cash (68,310) (160,220)
Cash, cash equivalents and restricted cash at beginning of period 382,742 445,615
Cash, cash equivalents and restricted cash at end of period 314,432 285,395
SUPPLEMENTAL INFORMATION:    
Interest paid 16,754 20,067
Income taxes paid (refunded), net (2,538) 19,861
Non-cash financing:    
Common stock options, warrants, and restricted stock units surrendered in net exercise $ 339 $ 213